

**IN THE CLAIMS:**

A<sup>4</sup>  
2. (Amended) A fragment of a monoclonal antibody, a peptide or a low molecular weight compound [of a monoclonal antibody] that induces apoptosis of nucleated blood cells having Integrin Associated Protein (IAP).

A<sup>5</sup>  
6. (Amended) The antileukemic agent according to claim 4, wherein the substance is a fragment of a monoclonal antibody, a peptide or a low molecular weight compound [of a monoclonal antibody].

Please add the following claims:

--7. The monoclonal antibody according to claim 1, wherein the IAP is of human origin.

A<sup>6</sup>  
8. The fragment, the peptide or the low molecular weight compound according to claim 2, wherein the IAP is of human origin.

9. A hybridoma that produces a monoclonal antibody as defined in claim 7.

10. The antileukemic agent according to claim 4, wherein the IAP is of human origin.

11. The antileukemic agent according to claim 10, wherein the substance is a monoclonal antibody.

Ab  
B<sup>1</sup>  
12. The antileukemic agent according to claim 10, wherein the substance is a fragment, a peptide or a low molecular weight compound of a monoclonal antibody.--

**REMARKS**

Applicants respectfully request entry of the foregoing amendment prior to the examination on the merits of the instant application. Should the Examiner have any questions or comments regarding the pending application or this Amendment, the Examiner is requested to call the undersigned.